Pharmaceuticals, Biotechnology and Life Sciences
ImmuPharma has completed patients recruitment regarding pivotal Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough…
Biocartis has today strenghten its collaboration with two companies; J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…
Abzena has granted USA-based Trieza an exclusive worldwide, royalty bearing, sub-licensable licence to an undisclosed antibody sequence, for exploitation in…
Advanced Oncotherapy has successfully tested and calibrated programme at ADAM in Geneva, and that made it possible to integrate the…
Hansa Medical AB has announced completion of a Phase II study entitled “A Phase II Study to Evaluate the Safety,…
Oasmia Pharmaceutical, a developer of a new generation of drugs within human and veterinary oncology, today presented positive results from…
Kiadis Pharma has announced an update on the second dose Phase II trial with ATIR101 (CR-AIR-008 ).
Galapagos has reported topline results from its Saphira 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837.
Belgian based biopharmaceutical company TiGenix has exercised the option granted by Takeda under the licensing agreement to make a EUR10…
U.S. Food and Drug Administration (“FDA”) has accepted Vernalis and Tris Pharma’s CCP-08 New Drug Application (“NDA”) for full review.…